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The CLN6 gene that causes variant late-infantile neuronal ceroid lipofuscinosis (vLINCL), a recessively inherited
neurodegenerative disease that features blindness, seizures, and cognitive decline, maps to 15q21-23. We have used
multiallele markers spanning this ∼4-Mb candidate interval to reveal a core haplotype, shared in Costa Rican
families with vLINCL but not in a Venezuelan kindred, that highlighted a region likely to contain the CLN6 defect.
Systematic comparison of genes from the minimal region uncovered a novel candidate, FLJ20561, that exhibited
DNA sequence changes specific to the different disease chromosomes: a GrT transversion in exon 3, introducing
a stop codon on the Costa Rican haplotype, and a codon deletion in exon 5, eliminating a conserved tyrosine
residue on the Venezuelan chromosome. Furthermore, sequencing of the murine homologue in the nclf mouse,
which manifests recessive NCL-like disease, disclosed a third lesion—an extra base pair in exon 4, producing a
frameshift truncation on the nclf chromosome. Thus, the novel ∼36-kD CLN6-gene product augments an intriguing
set of unrelated membrane-spanning proteins, whose deficiency causes NCL in mouse and man.
Introduction
The neuronal ceroid lipofuscinoses (NCLs) are the most
common neurodegenerative disorders of childhood
(Rider and Rider 1999). This group of diseases is char-
acterized by recessively inherited symptoms, including
progressive blindness, seizures, and dementia (Kohls-
chutter et al. 1993), and by hallmark proteolipid pig-
ment deposits in lysosomes of neurons and other cell
types (Wisniewski et al. 1988; Prasad et al. 1996). Eight
NCL subtypes, distinguished by age at clinical onset and
storage-body appearance (granular, fingerprint, and cur-
vilinear), reflect known genetic heterogeneity (Dyken
1989; Gardiner 2000).
The severe infantile (INCL; CLN1 [MIM 256730])
and late infantile (LINCL;CLN2 [MIM204500]) forms
are caused by deficiency of lysosomal palmitoyl-protein
thioesterase (Vesa et al. 1995) and of pepstatin-insen-
sitive peptidase (Sleat et al. 1997), respectively. Juvenile-
onset, or Batten disease (The International Batten Dis-
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ease Consortium 1995), which is the most common
NCL worldwide (JNCL; CLN3 [MIM 204200]) (Rider
and Rider 1988), Finnish progressive epilepsy withmen-
tal retardation (EPMR; CLN8) (Haltia et al. 1998), and
Finnish variant late-infantile NCL (vLINCL; CLN5
[MIM 256731]) (Savukoski et al. 1994) are due to de-
fects in novel membrane-spanning proteins (The Inter-
national Batten Disease Consortium 1995; Savukoski
et al. 1998; Ranta et al. 1999). Turkish variant LINCL
(Wheeler et al. 1998) (vLINCL; CLN7 [MIM 600143])
(Wheeler et al. 1999) may be allelic to CLN8, although
no disease-causing mutations have been identified
(Mitchell et al. 2001), and CLN6, linked to 15q21-23
markers, causes variant late-infantile disease (vLINCL;
CLN6 [MIM 601780]) in families of Indian ancestry
(Sharp et al. 1997) and in descendants of Spanish settlers
in Costa Rica (Haines et al. 1998).
Costa Rican vLINCL, clinically straddling LINCL
and JNCL, features small mixed storage bodies (cur-
vilinear and fingerprint profiles), intermediate onset of
symptoms at age 5–7 years, and a course that leads to
death in the affected individual’s mid 20s (Boustany
1997; Pena et al. 2001). The causative CLN6 defect
maps to an ∼6-cM segment of chromosome 15, between
D15S1020 and D15S1000 (Auger et al. 1999; Sharp et
al. 1999), although allele sharing in two affected sib-
lings, not common to other CLN6 kinships, has sug-
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gested an ∼4-cM subinterval (D15S988–D15S983)
(Sharp et al. 1999).
We have now employed a panel of multiallele poly-
morphic DNA markers, pursuing our location-cloning
strategy. A core Costa Rican haplotype, distinct from a
Venezuelan chromosome that suggests multiple origins
for the disease, narrowed the human candidate region,
localizing the CLN6 defect within a small gene-rich in-
terval. Sequence comparisons revealed differences in
FLJ20561, encoding a novel putative membrane-span-
ning protein. We identified distinct alterations—a trun-
cating change and a codon deletion, on the Costa Rican
and Venezuelan haplotypes, respectively, and a third de-
fect, a frameshift-truncating change, in the nclf mouse
featuring NCL-like disease with fingerprint deposits, ret-
inal atrophy, and paralysis (Bronson et al. 1998). The
presence of these alterations on disease chromosomes but
not on normal chromosomes strongly suggests that
FLJ20561 is theCLN6 gene and that its deficiency causes
NCL in mouse and in man.
Material and Methods
vLINCL Samples
Studies were performed with prior approval of the
institutional review boards (IRBs) atMassachusettsGen-
eral Hospital, Harvard Medical School, and Duke Uni-
versity Medical Center. Samples were collected from 13
Costa Rican families with LINCL and from a single Ve-
nezuelan sibship, comprising both parents and their af-
fected child. Lymphoblastoid cell lines were established
for most family members with Epstein-Barr virus (An-
derson and Gusella 1984). The clinical diagnosis of
vLINCL was determined by a single physician (R.-
M.N.B.) using standardized criteria (Haltia et al. 1998)
and was confirmed by mixed rectilinear- and fingerprint-
profile deposits observed by electron-microscopic ex-
amination of skin-biopsy samples. Eight Costa Rican
families were used in previous linkage studies, demon-
strating that the disease locus is allelic to CLN6 in
15q21-23 (Haines et al. 1998; Auger et al. 1999). All
of these families were collected pursuant to Duke IRB-
approved protocols.
Genotyping and Haplotype Analysis in Families with
vLINCL
Genomic DNA was extracted from blood samples and
lymphoblastoid cell lines by a standard protocol (The In-
ternational Batten Disease Consortium 1995). D15S213,
D15S153, D15S988, D15S1015, D15DS983, D15S1025,
D15S1000, andD15S216were genotyped by primer pairs
and PCR-amplification conditions recommended by the
Whitehead Institute/MIT Center for Genome Research.
Five new dinucleotidemarkers—MADH3gt,MAP2K5ca,
ITGA11ca, poly YE, and poly YG—were generated from
human 15q23 genomic-DNA sequence (UCSC Human
Genome Project Working Draft). The specific primer sets
and PCR-amplification conditions are presented in table
1, together with the allele frequencies found on normal
chromosomes, obtained by genotyping the unrelated par-
ents of CEPH (Foundation Jean Daussett CEPH) and Ve-
nezuelan reference pedigrees. For all markers, PCR anal-
yses were performed with 100 ng genomic DNA, 20 pmol
each primer, 0.5 U Taq polymerase, and [32P]-dGTP, with
optimized buffer, temperature, and cycling conditions.
PCR products, electrophoresed on 6% denaturing poly-
acrylamide gels, were detected by autoradiography using
XAR film (Kodak).
Marker haplotypes on normal and disease chromo-
somes were determined by tracking the inheritance of al-
leles in families with vLINCL. Table 1 shows alleles found
on Costa Rican and Venezuelan disease haplotypes. Dis-
ease chromosomes in Costa Rican pedigrees share alleles
at MADH3gt and ITGA11ca, found only rarely on nor-
mal chromosomes, which is consistent with suggested
linkage disequilibrium (Haines et al. 1998; Auger et al.
1999). The Venezuelan disease chromosome exhibits
marker alleles common to nondisease chromosomes.
Gene Identification and Mutation Analyses
The locations of DNA markers and genes within the
CLN6 region were determined by our reported 15q22-
15q23 YAC contig (Auger et al. 1999) and by search of
the 15q23 genomic-DNA sequence, provided by the Hu-
man Genome Project, for annotated known genes, ex-
pressed-sequence tags (ESTs), cDNAs, and predicted gene
segments (UCSC Human Genome Project Working
Draft). Mutation scanning was performed by use of spe-
cific primer sets, to PCR-amplify exons and splice junc-
tions. Single-strand conformational polymorphism
(SSCP) analysis was performed according to the method
of Orita et al. (1989), and PCR products, purified by a
QIAGEN PCR-purification kit, were sequenced by a
BigDyeTerminator Cycle Sequencing Kit (Applied Biosys-
tems), on an ABI Prism 377 automated sequencer. The
genotyping assay for the CLN6 G317T mutation was as
follows: the 228-bp exon 3 product, amplified, with 5′-
ACTGGGAGAAGGTGGTCAG-3′ and 5′-TGTGTCCC-
TGGAGCCAGTGAC-3′, for 30 cycles of 94C for 40 s,
50C for 40 s, and 72C for 1 min, was restricted with
XhoI and was electrophoresed on 3% agarose gels. For
the CLN6 exon 5 codon–deletion assay, PCR products,
amplified, by 5′-ACTGGGAGAAGGGTGGTCAG-3′and
5′-TGTGTCCCTGAGCCAGTGAC-3′, for 30 cycles of
94C for 40 s, 50C for 40 s, and 72C for 1 min, the
226-bpmutant and 229-bp normal PCRproducts, labeled
by incorporation of [32P]-dGTP, were displayed on 6%
Table 1
New CLN6-Region Polymorphisms (and Frequencies) on Normal Chromosomes
MARKER
PRIMER
(5′r3′)
TA
a
(C) ALLELEb Nc Hzd
CEPH
STANDARD (ALLELES)Forward Reverse
MADH3gt GGCCCACCATGTTATTCAG AAGTGCATGACTGCTGTATGTG 52.5 1 (.143) 12 .69 2801 (4, 4), 2802 (5, 7)
2 (.012) 1
3 (.024) 2
4 (.345) 29
5 (.31) 26
6 (.000) 0
7 (.167) 14
MAP2K5ca TACTTGGTGGGCTGAGGTG ATGCGATGAACAGTGAGAATG 52.6 1 (.016) 1 .58 2801 (2, 4), 2802 (4, 6)
2 (.145) 9
3 (.065) 4
4 (.662) 41
5 (.000) 0
6 (.113) 7
ITGA11ca GGAAGCATGTGGATGACAC AAGGATGGGAGGCAGTGTG 56.5 0 (.025) 2 .85 2801 (18, 18), 2802 (14, 14)
1 (.288) 23
10 (.013) 1
11 (.013) 1
12 (.013) 1
14 (.10) 8
15 (.038) 3
16 (.075) 6
17 (.113) 9
18 (.088) 7
19 (.025) 2
20 (.075) 6
21 (.050) 4
22 (.025) 2
23 (.025) 2
24 (.025) 2
Poly YE TCTATCAATGGACAAATGGGTG TCCAGGCTCATCCATGTT 50.8 1 (.125) 7 .57 2801 (2, 2), 2802 (2, 5)
2 (.321) 18
3 (.089) 5
4 (.018) 1
5 (.071) 4
6 (.089) 5
7 (.268) 15
8 (.018) 1
Poly YG TTTAGTGGGCTCAATTATGACC TACGTTGCCCAGGATGAT 51.5 1 (.015) 1 .71 2801 (9, 12), 2802 (12, 12)
1 (.015) 1
2 (.059) 4
3 (.074) 5
4 (.015) 1
5 (.103) 7
7 (.015) 1
8 (.029) 2
9 (.162) 11
10 (.176) 12
11 (.015) 1
12 (.309) 21
13 (.015) 1
a Annealing temperature.
b Data in parentheses are allele frequencies. Alleles in boldface italic are on the Costa Rican disease haplotype; underlined alleles are on the
Venezuelan haplotype.
c No. of normal chromosomes.
d Heterozygosity.
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polyacrylamide gels. The parents of CEPH (Foundation
Jean Daussett CEPH) and Venezuela DNA genetic-ref-
erence pedigrees served as a source of unrelated non-dis-
ease chromosomes.
The coding region of the mouse FLJ20561 homologue
(mCG9290 [Celera sequence 55053941–55061138])
was analyzed by DNA sequencing of exon-specific PCR
products amplified from various wild-type mouse and
nclf mouse genomic DNA (stock JR2648; The Jackson
Laboratories). For the nclf-mutation assay, exon 4 PCR
product was amplified, by 5′ CATACTAGTTTGGGTG-
ACAGTAGACAAACAG-3′ and 5′-CCACCATGATCA-
GTAGCTAGGCTG-3′, for 30 cycles of 94C for 40 s,
58C for 40 s, and 72C for 1 min. The 510-bp mutant
and 509-bp wild-type products were purified, and their
DNA sequences were determined.
Northern Blot and RT-PCR Analyses
Multiple-tissue northern blots were hybridized ac-
cording to the manufacturer’s protocol (Clontech).
Probes were generated by PCR amplification of human
exon 7 and mouse exons 2–7. PCR products were pu-
rified by the QIAQuick PCR purification kit (Qiagen)
and were [32P]-labeled with the RadPrime DNA labeling
system (Gibco BRL). Hybridization was performed with
ExpressHyb Hybridization Solution (Clontech) at 65C.
RT-PCR analysis was performed by TheOne Step system
(Invitrogen).
Results
Refining the CLN6 Region
The CLN6 candidate region, defined by recombina-
tion events in families with vLINCL, spans ∼4 Mb of
15q22-23 DNA between D15S1020 and D15S1000
(Auger et al. 1999; Sharp et al. 1999). To refine this
region, we followed the strategy depicted in figure 1A,
initially using a panel of multiallele DNA markers to
reveal the haplotypes of the disease chromosomes in our
collection of 13 Costa Rican families with vLINCL and
a single Venezuelan nuclear sibship with vLINCL. The
data, summarized in figure 1B, indicate that all Costa
Rican disease chromosomes exhibit a common haplo-
type, whereas both Venezuelan disease chromosomes
share an apparently unrelated haplotype, suggesting that
there are two independent mutational origins of v-
LINCL. Moreover, within the Costa Rican disease hap-
lotype, a core region of shared marker alleles places
CLN6 between two of our new polymorphic markers,
MADH3gt and polyYE (see the “Material and Meth-
ods” section).
Identification of a Candidate CLN6 Gene
The narrowed CLN6 genetic region, near the cen-
tromeric portion of our cloned YAC contig (Auger et al.
1999), is represented in 15q22-23 DNA sequence re-
ported by the Human Genome Project. Searches using
the Genome Browser server (UCSC Human Genome
Project Working Draft) revealed that MADH3gt and
poly YE flank an ∼1.6-Mb interval that contains at least
11 annotated genes encoding known or predicted pro-
teins (fig. 1A).
To identify potential CLN6 mutations, we systemat-
ically scanned the coding segments of each candidate
gene, for disease-specific DNA sequence changes, by
comparing the PCR products amplified from patients
and normal controls. Direct DNA sequencing and SSCP
analyses did not reveal differences in any of the known
genes—MADH3 (mothers against decapentaplegic ho-
mologue), MAP2K5 (mitogen-activated protein kinase
kinase5), DDXBP1 (DEAD/H box binding protein),
FEM1B (feminization factor), and ITGA11 (integrin,
alpha 11)—or in three (GenBank accession numbers
AF308287, AL13356, and FLJ12476) of five novel
mRNAs in GenBank. By contrast, alterations were iden-
tified in a hypothetical protein, FLJ20561, that is located
betweenDDXBP1 and FEM1B (fig. 1A). This novel full-
length (2.3-kb) cDNA comprises seven exons that span
∼22.7 kb of 15q23 genomic DNA, with, in exon 1, an
ATG start codon predicting a novel 311-amino-acid
protein.
FLJ20561 Coding Sequence Mutations on vLINCL
Chromosomes
Figure 2 presents the FLJ20561 DNA sequence
changes that we identified on disease chromosomes. The
Costa Rican haplotype carries a GrT nucleotide change
at bp 317 in exon 3 (fig. 2A), evident both in PCR
products from an affected child (homozygous) and, in
a heterozygous state, in a transmitting parent. This trans-
version, creating a premature stop codon, was present
on all 28 Costa Rican disease chromosomes but was not
found in the Venezuelan family. Furthermore, as shown,
a direct genotyping assay, involving XhoI restriction to
distinguish the transversion, confirmed recessive coin-
heritance of the alteration and the disease in Costa Rican
families. This change was not found on 332 normal
chromosomes (from 150 unrelated individuals and 32
independent FLJ20561 sequences in databases), provid-
ing evidence that the transversion causes vLINCL in pa-
tients with the Costa Rican haplotype.
The Venezuelan vLINCL chromosome possesses an
exon 5 CTA codon deletion at bp 613, predicted to
eliminate tyrosine 171 (DY171). As shown in figure 2B,
the affected child has inherited the change from both
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Figure 1 Narrowing the CLN6 region on human chromosome 15. A, Schematic of locations of DNA markers that delimit the genomic 15q22-
23 DNA that must contain the CLN6 gene (top), drawn on the basis of data from the Human Genome Project (UCSCHumanGenome ProjectWorking
Draft). Reported recombination events in families with vLINCL place the gene between D15S1020 and D15S216 (gray-stippled sections). The shared
core Costa Rican haplotype points to the segment between MADH3gt and poly YE (black-stippled section). The middle line depicts genomic 15q23
DNA sequence, with the location of gaps (paired slashes), ESTs, and predicted and known genes (arrows) (UCSC Human Genome Project Working
Draft). The location of FLJ20561 (blue) is shown, and its predicted exon-intron structure is given, with the coding region shaded (bottom). B, Results
of haplotype analysis in Costa Rican and Venezuelan families. Alleles for DNA markers that span the CLN6 region are shown for 27 independent
Costa Rican (CR1–CR27) and 2 Venezuelan (VZ1 and VZ2) disease chromosomes. Three chromosomes, distinguished by apparent recombination
events (indicated by asterisks [*]), are from two affected Costa Rican siblings. Shared alleles (gray-shaded boxes) indicate a common haplotype that,
for chromosomes CR1–CR15 also includes D15S1020, D15S1025, D15S1000, and D15S216 (not shown). Lack of allele sharing (unshaded boxes) at
MADHG3gt and poly YE delimits a core Costa Rican haplotype and reveals an unrelated Venezuelan vLINCL chromosome. The “21”’ allele at
ITGA11ca is likely to be derived from the “19” allele by slippage. TheMAP2K5ca “4”’ allele is also common to normal chromosomes (see the “Material
and Methods” section).
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Figure 2 Candidate CLN6 mutations in human and mouse FLJ20561. A, G317T mutation, in exon 3, found on Costa Rican disease
chromosomes. On the left are ABI Prism 377 sequence traces showing the reverse strand of exon 3 PCR products amplified from a normal
control, from a Costa Rican patient (homozygote), and from a transmitting parent (heterozygote). The CrA change (underlined) results in the
loss of an XhoI site, permitting a direct genotyping assay, the results of which are shown on the right. The ethidium bromide–stained agarose
gel reveals two XhoI fragments (of 175 bp and 53 bp) for the normal allele and a single XhoI fragment (228 bp) for the mutant allele. The
results demonstrate coinheritance of the mutant allele and clinically diagnosed disease (black square), inherited with the disease chromosome
transmitted from each carrier parent (symbols containing dots), which is also detected in an unaffected carrier sibling. B, CTA deletion in exon
5 (producing the DY171 change in the protein), which is found on both Venezuelan vLINCL chromosomes. On the left are ABI Prism 377
sequence traces of the exon 5 products amplified from a normal control, from the affected Venezuelan child who is homozygous for the DY171
change, and from a heterozygous transmitting parent. The deletion produces a shorter (226 bp) PCR product, permitting a direct genotyping
assay, the results of which are shown on the right. The autoradiograph shows radiolabeled exon 5 PCR products—226 bp for the mutant allele
and 229 bp for the normal allele—found in the parents. C, Extra C-nucleotide insertion in exon 4 (producing the R103 frameshift change in
the protein), which is found on the nclf chromosome. Shown are ABI Prism 377 sequence traces (for the reverse strand) of exon 4 PCR products
amplified from wild-type mouse DNA and from nclf/nclf mouse DNA. Direct sequencing did not reveal this change in products amplified from
several inbred strains of mice, from outbred mice, or from wild mice.
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Figure 3 Human and mouse proteins encoded by FLJ20561 cDNA homologues. The top line in each pair shows the predicted 311-amino-
acid open reading frame of the FLJ20561 cDNA. Below this line are differences unique to the 308-amino-acid mouse protein, predicted on the
basis of the murine cDNA sequence. Sequences were aligned by BLAST 2 Sequences (also see the NCBI BLAST web site). Dashes (–) represent
gaps in the match. The positions of six predicted introns (numbered 1–6), delineating seven exons, were determined by alignment of cDNA
and genomic-DNA sequences (UCSC Human Genome Project Working Draft and Celera database). The stop mutation found on Costa Ri-
can–haplotype disease chromosomes is indicated by an “at” symbol (@), the DY171 deletion mutation on Venezuelan disease chromosomes is
indicated by an arrow, and the position of the frameshift, produced by the extra C nucleotide, on the nclf chromosome is indicated by an
asterisk (*). The latter change leads to a stop codon after a run of 61 novel amino acids (PNAAAVYSLCQHHHFHHGSQHPPGGRLSQPS-
PALQWVPAPPVRQ REPHYQEPQAGDSDRLL&) that are not shown.
the mother and the father. This change was not detected
on Costa Rican chromosomes, and a direct genotyping
assay (fig. 2B) did not reveal the alteration on any of
324 normal chromosomes (from 148 unrelated people
and 28 independent ESTs). Thus, consistent with a dis-
tinct haplotype, vLINCL in the Venezuelan kindred ap-
pears to be caused by a second mutation, confirming the
existence of independent origins of this disease in man.
FLJ20561 Sequence Change on the Murine nclf
Chromosome
nclf, a spontaneous mouse mutation causing a reces-
sively inherited NCL-like disease with hallmark storage
deposits, retinal atrophy, and paralysis, maps to a mouse
chromosome 9 region that is syntenic with human
15q21-23, making it a likely CLN6 homologue (Bron-
son et al. 1998). Searches of GenBank and the Cel-
era Mouse Gene database with the human FLJ20561
sequence disclosed matches to mouse chromosome 9 ge-
nomic sequence, disclosing identities to a predicted gene,
mCG9290. The mouse FLJ20561 homologue, as illus-
trated in figure 3, encodes a predicted 308-amino-acid
protein that is highly identical (90.3% overall ami-
no acid identity [BLAST 2]) to its human counterpart.
Furthermore, the chromosome 9 matches reveal both an
exon-intron organization that mirrors the human gene
and, for the mouse homologue, a location between
the murine Ddxbp1 (mCG9281 [Celera sequence
55084931–55182946]) and Fem1b (mCG9291 [Celera
sequence 55005793–55020906) homologues, which
is flanked by Map2k5 (mCG9283 [Celera sequence
55363607–55576330]) and Itga11 (mCG10167–
mCG10169 [Celera sequence 54887579–54992508])
and which is in a region of synteny with the human
15q23 CLN6 region (fig. 1A). This location is consistent
with the genetic position of nclf in a 0.18-cM interval
determined with 535 backcross and 2,803 intercross
progeny: D9Mit164–0.37 cM–D9Mit234–0.05 cM–
D9Mit208,B5,B3–0.06 cM–B6–0.16 cM–B2,B4,nclf–
0.02 cM–B1–0.08 cM–D9Mit338,D9Mit105,B7–0.26
cM–D9Mit106 (B1–B7 microsatellite primer informa-
tion is available from J.R.F.).
Sequencing of murine FLJ20561 exons, amplified
from nclf/nclf genomic DNA, revealed that the nclf chro-
mosome carries, in exon 4, an extra cytidine (C) that
extends a normal run of six Cs to seven nucleotides (fig.
2C), predicting a frameshift that results in a premature
stop codon. This change was not found by direct se-
quence analysis of PCR products amplified from either
inbred mouse strains (C57BL/6, BALB/c, and C3H), out-
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bred CD1 mice, or wild-mouse stocks. Nor was it found
in mouse (or human) FLJ20561 ESTs or cDNAs iden-
tified in the databases. Thus, a single-base insertion in
the FL20561 gene is the likely cause of recessively in-
herited NCL-like disease in the nclf mouse.
CLN6-Gene Products
Northern blot analyses, shown in figure 4A, reveal ex-
pression of FLJ20561 mRNA in mouse and human, both
in adult and embryonic brain and in peripheral tissues.
A major ∼2.4-kb band matches the size of the full-length
FLJ20561 cDNA, and the wide expression pattern is con-
sistent with ESTs and cDNAs in human and mouse da-
tabases. Notably, some of these ESTs and cDNAs lack
exons 4 or 5, suggesting some alternative splicing. Fur-
thermore, as shown for the mouse, full-length cDNA
probes also reveal an ∼5.5-kb band that may represent
either a much larger FLJ20561 isoform or, alternatively,
a product from a related gene. The FLJ20561 ATG codon
in exon 1 is located within an optimal Kozak consensus
sequence, suggesting that Met1, shown in figure 3, is the
start of translation. The genomic-DNA sequence up-
stream of exon 1 lacks a canonical TATA box but features
a GC-rich genomic-DNA sequence that may be a pro-
moter region (MatInspector program).
FLJ20561 is novel, and, in addition to the mouse
gene, EST-sequence identities indicate likely homo-
logues in a variety of species, including cow (GenBank
accession number BE483775), pig (GenBank accession
number BE014837), chicken (GenBank accession num-
ber BI389620), and Xenopus laevis (GenBank accession
number AW644932). The mouse and human versions
share high amino acid identity across the entire protein,
including, as illustrated by the hydropathy plot in figure
4B, approximately six predicted membrane-spanning
domains that strongly suggest an integral membrane
protein. The exception is the relatively poorly conserved
amino-terminal segment, encoded by exon 1, which may
represent a mitochondrial presequence predicted by
PSORT II, MITOPROT II (Claros and Vincens 1996),
and CBS TargetP (score 0.86) (Nielsen et al. 1997;
Emanulelsson et al. 2000). These programs predict a
cleavage site, after a conserved histidine, that may ex-
pose the internal glycine residue to N-myristoylation
(PredictProtein). Conserved serine and threonine resi-
dues may be potential sites of phosphorylation by casein
kinase II and PKC, although N-glycosylation sites are
not predicted.
Impact of the Mutations
RT-PCR amplification of RNA isolated from lympho-
blastoid cells of an affected Costa Rican patient reveals
that the truncating mutation in exon 3 does not eliminate
mRNA expression from the disease allele (data not
shown). Thus, although a quantitative effect at the
mRNA level is not ruled out, the exon 3 change, as well
as the exon 4 and exon 5 mutations that we have iden-
tified, may, instead, critically alter the protein product.
The Costa Rican CLN6 and nclf mRNAs are expected
to encode severely truncated products—of 72 and 103
residues (plus 61 novel amino acids), respectively—
which, if stable, are likely to be nonfunctional. Loss of
a single tyrosine residue, one of an unusual triplet at a
transmembrane junction, causes similar disease in the
Venezuelan child, implying a site that is absolutely crit-
ical to the activity of this novel integral membrane
protein.
Discussion
The discovery of two mutations on different vLINCL
chromosomes, both in Costa Rican families and in a
Venezuelan kinship, and of a third defect in the nclf
mouse suggest that the CLN6 gene has been identified.
The clinical and neuropathologic features of the delayed
late-infantile-onset form of NCL, therefore, stem from
disruption of a novel ∼36-kD membrane-spanning pro-
tein. Historically, mutations that cause vLINCL in man
have occurred on at least two occasions and, given the
lack of allele sharing in families of Asian and Indian
ancestry that have vLINCL (Sharp et al. 1999), it is likely
that additional CLN6 mutations will be uncovered. It
is also possible that a common founder mutation—
which may but need not be related to either the Costa
Rican or the Venezuelan defect—will be found; for ex-
ample, Indian, Pakistani, and Romany gypsy families
with vLINCL, families that may share ancestry (Bennett
and Hofmann 1999), may also possess a common
mutation.
The spontaneous murine nclf mutation, currently the
only CLN6 lesion known in the mouse, has revealed,
in neurons and other cell types, early deposits that pres-
age later retinal atrophy, reactive gliosis, and neuronal-
cell degeneration (Bronson et al. 1998). These mice,
therefore, offer an immediate resource for studies to
discover very early pathological changes that can be
investigated in human vLINCL tissue. Moreover, ad-
ditional nonhuman CLN6 defects are likely to emerge
from a variety of naturally occurring NCL animal mod-
els (Jolly et al. 1992), particularly that for the OCL6
defect in Southampshire sheep (Broom et al. 1998,
1999), which has revealed mitochondrial ATP synthase
subunit c in NCL-storage bodies (Jolly 1997; Broom et
al. 1998).
Knowledge of the fundamental CLN6 defects in an-
imal models, together with mutations in man, will pro-
vide genotype-phenotype information that may be crit-
ical for unraveling of the function of the novel CLN6
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Figure 4 Comparison of human andmouseCLN6-gene products.A,Results of human andmousemultiple-tissue northern blots (Clontech),
demonstrating wide expression, in brain and peripheral tissues. The human-adult-tissue northern blot was probed with an ∼700-bp FLJ20561
exon 7 probe, revealing an ∼2.4-kb mRNA, matching the size of the full-length cDNA. The mouse-adult tissue and whole-embryo northern
blots were hybridized with a ∼1.1-kb probe (exons 2–7), which detects the 2.4-kb mRNA and an unexpected ∼5.5-kb band. A full-length
FLJ20561 probe also detects a 5.5-kb band in human tissues (data not shown). P p pancreas; K p kidney; skM p skeletal muscle; Lv p
liver; Lg p lung; Pl p placenta; B p brain; H p heart; T p testis; Sp p spleen; E17 p embryonic day 17; E15 p embryonic day 15; E11
p embryonic day 11; E7 p embryonic day 7. B, Hydropathy-plot overlay of predicted human and mouse proteins. Hydropathy plots, drawn
according to the Kyte-Doolittle x-1 method (window length 19), by use of the Weizmann Institute of Science Genome and Bioinformatics,
Protein Hydrophilicity/Hydrophobicity Search and Comparison server, are nearly identical for the human and mouse proteins, with the exception
of the amino terminus. Positive values indicate calculated hydrophobic values. Conserved serine/threonine phosphorylation sites are indicated
by circles. The location of the “Costa Rican” exon 3 stop codon is indicated by an “at” symbol (@); the “nclf” mouse exon 4 frameshift lesion
is indicated by an asterisk (*), and the “Venezuelan” exon 5 DY171 change is indicated by an arrow. Below the plot is an alignment of the
amino-terminal regions of the human and mouse proteins. A conserved putative N-myristoylation site (“lollipop” symbol) predicted by
PredictProtein may become exposed on cleavage (vertical bar) of a putative presequence predicted by the PSORT II and CBS TargetP programs.
protein. The CLN6-encoded protein, which we have
dubbed “linclin” (for LINCL protein), is novel, without
obvious relatives or protein domains that readily place
it within a biochemical or functional pathway. The pro-
tein is, however, highly identical between man and
mouse. The exception is the amino terminus, whichmay
serve as a cleaved mitochondrion-targeting leader se-
quence, with subsequent glycine myristoylation perhaps
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anchoring the processed amino terminus in the
membrane. The protein is predicted to form approxi-
mately six membrane-spanning domains, although it
may lack N-glycosylation sites, suggesting that it may
not mature via the secretory system. Another potential
clue is a region between transmembrane segments, iden-
tical in man and mouse, that contains multiple histidine
residues and an unusual tyrosine triplet, implying a do-
main that is essential to the protein’s unknown func-
tional activities.
The recessively inherited CLN6 mutations that we
have identified cause identical disease in Costa Rican
and Venezuelan sibships. The severely truncated mutant
product, comprising the putative presequence and two
transmembrane domains, predicted for the Costa Rican
(and nclf) mutation implies a complete loss of functional
activity; this loss apparently can be mirrored by the
Tyr171 deletion. This strongly implies that Tyr171—or
the surrounding putative domain—may be directly in-
volved in the biochemical activity of the protein.
Linclin joins three unrelated transmembrane pro-
teins—encoded by CLN3, CLN5, and CLN8—that,
when disrupted, cause NCL symptoms that begin in
school-age children. Moreover, CLN8, which causes
EPMR in man (Ranta et al. 1999), is also mutated in
themndmouse (Messer et al. 1992; Bronson et al. 1993;
Ranta et al. 1999), producing disease that is identical
to that caused by the truncating nclfmutation (Bronson
et al. 1998). This close similarity in their “loss of func-
tion” phenotypes therefore suggests that theCLN6- and
CLN8-gene products, as well as the protein products
of CLN5 and CLN3, may either be in parallel bio-
chemical pathways or, perhaps, comprise a functional
complex.
Deficiencies for classic lysosomal enzymes cause severe
(rapid-onset) disease in infants, and the presence of ly-
sosomal inclusions had suggested classification of the
NCLs as “lysosomal”-storage disorders (Bennett and
Hofmann 1999). However, CLN3, CLN5, CLN8, and
CLN6 all encode novelmembrane-spanning proteins that
may not be restricted to the lysosome (Janes et al. 1996;
Pearce 2000). Defects in each of these novel loci cause
onset of symptoms after infancy (at age years),13–62
suggesting effects, on essential processes, that are less
acute than the loss of lysosomal components. Thus, the
novel linclin, battenin, and CLN5- and CLN8-encoded
transmembrane proteins may comprise components of
an “upstream” pathway that, if perturbed, eventually
leads to lysosomal lipoprotein deposits.
Elucidation of the CLN6 gene will permit carrier test-
ing and will allow accurate diagnosis of delayed infan-
tile forms of NCL, offering improved disease manage-
ment. Furthermore, knowledge of CLN6 will spur
genotype-phenotype studies in patients with NCL and
in spontaneous and created animal models, which
promise to shed light on pathways critical for neurons.
It is hoped that this knowledge will provide a complete
understanding of the biochemical deficits that cause
NCL, leading to the development of rational therapeutic
interventions for these tragic disorders.
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